Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population
Study Type – Diagnostic (exploratory cohort) Level of Evidence 2b OBJECTIVE To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high‐risk men with a low baseline prostate‐specific antigen (PSA) level and enrolled in the Prostate...
Gespeichert in:
| Veröffentlicht in: | BJU international 2010-02, Vol.105 (3), p.334-337 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 337 |
|---|---|
| container_issue | 3 |
| container_start_page | 334 |
| container_title | BJU international |
| container_volume | 105 |
| creator | Kaplan, David J. Boorjian, Stephen A. Ruth, Karen Egleston, Brian L. Chen, David Y. T. Viterbo, Rosalia Uzzo, Robert G. Buyyounouski, Mark K. Raysor, Susan Giri, Veda N. |
| description | Study Type – Diagnostic (exploratory cohort)
Level of Evidence 2b
OBJECTIVE
To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high‐risk men with a low baseline prostate‐specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history.
PATIENTS AND METHODS
Eligibility for PRAP includes men aged 35–69 years who are African‐American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates.
RESULTS
In all, 624 participants were evaluated, including 382 (61.2%) African‐American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0–69.0) years and the median PSA level 0.9 (0.1–27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P |
| doi_str_mv | 10.1111/j.1464-410X.2009.08793.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2809782</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733614235</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5033-c42c6e7f8bd0a0415e94a3aad34ba908614263d33c65e518a1f91c33fea9db7b3</originalsourceid><addsrcrecordid>eNqNkc1u1DAQxy0EoqXwCsgXxGnDOM6XDyDBqnypEgi1Ejdr4kw2XrLxYidLe-MReEaeBKe7LHDDF894fjP-a_6McQGJiOfZOhFZkS0yAZ-TFEAlUJVKJtd32OmxcPd3DKo4YQ9CWAPEhyK_z06EKkFBmZ6y7nyH_YSjdQN3LR874h-9CyOOxJc4GPIxpx0Nt8Slt9jzTzZ84QZ7M_U4Os_twJF3dtX9_P7Dz7VgPNFghxXfuu0Mxd6H7F6LfaBHh_uMXb0-v1y-XVx8ePNu-fJiYXKQcmGy1BRUtlXdAEImclIZSsRGZjUqqAqRpYVspDRFTrmoULRKGClbQtXUZS3P2Iv93O1Ub6gxUbnHXm-93aC_0Q6t_rcy2E6v3E6nFaiySuOAp4cB3n2dKIx6Y4OhvseB3BR0KeUsQuaRrPakiRsLntrjLwL07JNe69kCPduhZ5_0rU_6OrY-_lvln8aDMRF4cgAwxFW3Pnphw5FLUwlKlhC553vum-3p5r8F6Ffvr-ZI_gKpEbJi</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733614235</pqid></control><display><type>article</type><title>Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Kaplan, David J. ; Boorjian, Stephen A. ; Ruth, Karen ; Egleston, Brian L. ; Chen, David Y. T. ; Viterbo, Rosalia ; Uzzo, Robert G. ; Buyyounouski, Mark K. ; Raysor, Susan ; Giri, Veda N.</creator><creatorcontrib>Kaplan, David J. ; Boorjian, Stephen A. ; Ruth, Karen ; Egleston, Brian L. ; Chen, David Y. T. ; Viterbo, Rosalia ; Uzzo, Robert G. ; Buyyounouski, Mark K. ; Raysor, Susan ; Giri, Veda N.</creatorcontrib><description>Study Type – Diagnostic (exploratory cohort)
Level of Evidence 2b
OBJECTIVE
To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high‐risk men with a low baseline prostate‐specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history.
PATIENTS AND METHODS
Eligibility for PRAP includes men aged 35–69 years who are African‐American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates.
RESULTS
In all, 624 participants were evaluated, including 382 (61.2%) African‐American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0–69.0) years and the median PSA level 0.9 (0.1–27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason ≥7 prostate cancer vs 15.2% in all other participants (P < 0.001).
CONCLUSION
The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African‐American men with a low baseline PSA level. These results support further evaluation of this predictive tool for assessing the risk of prostate cancer in high‐risk men.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2009.08793.x</identifier><identifier>PMID: 19709072</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; African Americans ; Aged ; Biological and medical sciences ; biopsy ; calculator ; Early Detection of Cancer - methods ; Gynecology. Andrology. Obstetrics ; Humans ; Kaplan-Meier Estimate ; Male ; Male genital diseases ; Mass Screening - standards ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Pedigree ; prediction ; prevention ; prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - prevention & control ; race ; Risk Assessment - methods ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>BJU international, 2010-02, Vol.105 (3), p.334-337</ispartof><rights>2009 THE AUTHORS. JOURNAL COMPILATION © 2009 BJU INTERNATIONAL</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5033-c42c6e7f8bd0a0415e94a3aad34ba908614263d33c65e518a1f91c33fea9db7b3</citedby><cites>FETCH-LOGICAL-c5033-c42c6e7f8bd0a0415e94a3aad34ba908614263d33c65e518a1f91c33fea9db7b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1464-410X.2009.08793.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1464-410X.2009.08793.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22309370$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19709072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaplan, David J.</creatorcontrib><creatorcontrib>Boorjian, Stephen A.</creatorcontrib><creatorcontrib>Ruth, Karen</creatorcontrib><creatorcontrib>Egleston, Brian L.</creatorcontrib><creatorcontrib>Chen, David Y. T.</creatorcontrib><creatorcontrib>Viterbo, Rosalia</creatorcontrib><creatorcontrib>Uzzo, Robert G.</creatorcontrib><creatorcontrib>Buyyounouski, Mark K.</creatorcontrib><creatorcontrib>Raysor, Susan</creatorcontrib><creatorcontrib>Giri, Veda N.</creatorcontrib><title>Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Study Type – Diagnostic (exploratory cohort)
Level of Evidence 2b
OBJECTIVE
To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high‐risk men with a low baseline prostate‐specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history.
PATIENTS AND METHODS
Eligibility for PRAP includes men aged 35–69 years who are African‐American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates.
RESULTS
In all, 624 participants were evaluated, including 382 (61.2%) African‐American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0–69.0) years and the median PSA level 0.9 (0.1–27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason ≥7 prostate cancer vs 15.2% in all other participants (P < 0.001).
CONCLUSION
The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African‐American men with a low baseline PSA level. These results support further evaluation of this predictive tool for assessing the risk of prostate cancer in high‐risk men.</description><subject>Adult</subject><subject>African Americans</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>biopsy</subject><subject>calculator</subject><subject>Early Detection of Cancer - methods</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Mass Screening - standards</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Pedigree</subject><subject>prediction</subject><subject>prevention</subject><subject>prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Prostatic Neoplasms - prevention & control</subject><subject>race</subject><subject>Risk Assessment - methods</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAQxy0EoqXwCsgXxGnDOM6XDyDBqnypEgi1Ejdr4kw2XrLxYidLe-MReEaeBKe7LHDDF894fjP-a_6McQGJiOfZOhFZkS0yAZ-TFEAlUJVKJtd32OmxcPd3DKo4YQ9CWAPEhyK_z06EKkFBmZ6y7nyH_YSjdQN3LR874h-9CyOOxJc4GPIxpx0Nt8Slt9jzTzZ84QZ7M_U4Os_twJF3dtX9_P7Dz7VgPNFghxXfuu0Mxd6H7F6LfaBHh_uMXb0-v1y-XVx8ePNu-fJiYXKQcmGy1BRUtlXdAEImclIZSsRGZjUqqAqRpYVspDRFTrmoULRKGClbQtXUZS3P2Iv93O1Ub6gxUbnHXm-93aC_0Q6t_rcy2E6v3E6nFaiySuOAp4cB3n2dKIx6Y4OhvseB3BR0KeUsQuaRrPakiRsLntrjLwL07JNe69kCPduhZ5_0rU_6OrY-_lvln8aDMRF4cgAwxFW3Pnphw5FLUwlKlhC553vum-3p5r8F6Ffvr-ZI_gKpEbJi</recordid><startdate>201002</startdate><enddate>201002</enddate><creator>Kaplan, David J.</creator><creator>Boorjian, Stephen A.</creator><creator>Ruth, Karen</creator><creator>Egleston, Brian L.</creator><creator>Chen, David Y. T.</creator><creator>Viterbo, Rosalia</creator><creator>Uzzo, Robert G.</creator><creator>Buyyounouski, Mark K.</creator><creator>Raysor, Susan</creator><creator>Giri, Veda N.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201002</creationdate><title>Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population</title><author>Kaplan, David J. ; Boorjian, Stephen A. ; Ruth, Karen ; Egleston, Brian L. ; Chen, David Y. T. ; Viterbo, Rosalia ; Uzzo, Robert G. ; Buyyounouski, Mark K. ; Raysor, Susan ; Giri, Veda N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5033-c42c6e7f8bd0a0415e94a3aad34ba908614263d33c65e518a1f91c33fea9db7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>African Americans</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>biopsy</topic><topic>calculator</topic><topic>Early Detection of Cancer - methods</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Mass Screening - standards</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Pedigree</topic><topic>prediction</topic><topic>prevention</topic><topic>prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Prostatic Neoplasms - prevention & control</topic><topic>race</topic><topic>Risk Assessment - methods</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaplan, David J.</creatorcontrib><creatorcontrib>Boorjian, Stephen A.</creatorcontrib><creatorcontrib>Ruth, Karen</creatorcontrib><creatorcontrib>Egleston, Brian L.</creatorcontrib><creatorcontrib>Chen, David Y. T.</creatorcontrib><creatorcontrib>Viterbo, Rosalia</creatorcontrib><creatorcontrib>Uzzo, Robert G.</creatorcontrib><creatorcontrib>Buyyounouski, Mark K.</creatorcontrib><creatorcontrib>Raysor, Susan</creatorcontrib><creatorcontrib>Giri, Veda N.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaplan, David J.</au><au>Boorjian, Stephen A.</au><au>Ruth, Karen</au><au>Egleston, Brian L.</au><au>Chen, David Y. T.</au><au>Viterbo, Rosalia</au><au>Uzzo, Robert G.</au><au>Buyyounouski, Mark K.</au><au>Raysor, Susan</au><au>Giri, Veda N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2010-02</date><risdate>2010</risdate><volume>105</volume><issue>3</issue><spage>334</spage><epage>337</epage><pages>334-337</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>Study Type – Diagnostic (exploratory cohort)
Level of Evidence 2b
OBJECTIVE
To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high‐risk men with a low baseline prostate‐specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history.
PATIENTS AND METHODS
Eligibility for PRAP includes men aged 35–69 years who are African‐American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates.
RESULTS
In all, 624 participants were evaluated, including 382 (61.2%) African‐American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0–69.0) years and the median PSA level 0.9 (0.1–27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason ≥7 prostate cancer vs 15.2% in all other participants (P < 0.001).
CONCLUSION
The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African‐American men with a low baseline PSA level. These results support further evaluation of this predictive tool for assessing the risk of prostate cancer in high‐risk men.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19709072</pmid><doi>10.1111/j.1464-410X.2009.08793.x</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2010-02, Vol.105 (3), p.334-337 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2809782 |
| source | MEDLINE; Wiley Journals |
| subjects | Adult African Americans Aged Biological and medical sciences biopsy calculator Early Detection of Cancer - methods Gynecology. Andrology. Obstetrics Humans Kaplan-Meier Estimate Male Male genital diseases Mass Screening - standards Medical sciences Middle Aged Nephrology. Urinary tract diseases Pedigree prediction prevention prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - genetics Prostatic Neoplasms - prevention & control race Risk Assessment - methods Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A52%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20Prostate%20Cancer%20Prevention%20Trial%20Risk%20calculator%20in%20a%20high%E2%80%90risk%20screening%20population&rft.jtitle=BJU%20international&rft.au=Kaplan,%20David%20J.&rft.date=2010-02&rft.volume=105&rft.issue=3&rft.spage=334&rft.epage=337&rft.pages=334-337&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/j.1464-410X.2009.08793.x&rft_dat=%3Cproquest_pubme%3E733614235%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733614235&rft_id=info:pmid/19709072&rfr_iscdi=true |